Payment overview · 2025
General Payments
$1,795.96
52 reported records · 15 companies
Healthcare provider profile · identity verified
Abdullah Arshad, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAYTI, MO · NPI 1477660637
Verified facts
What the public records show
CMS Open Payments records show Abdullah Arshad, MD received $1,795.96 in general payments during 2025 across 52 reported records.
Janssen Pharmaceuticals, Inc accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Farxiga, Gemtesa, Jardiance, Rexulti, Trelegy Ellipta, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Aristada by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 813 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 813 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $754.39 | 42.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $321.79 | 17.9% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.84 | 6.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $115.72 | 6.4% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $84.60 | 4.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $75.41 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.40 | 4.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $59.48 | 3.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.27 | 1.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.10 | 1.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.71 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.21 | 1.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.51 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.29 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.24 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $927.63 | 47 |
| Travel and Lodging | $754.39 | 1 |
| Education | $113.94 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $754.39 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $321.79 | 16 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $321.79 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $234.56 | 10 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $84.60 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $75.41 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.40 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 294 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 184 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 214 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 267 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
294 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
259 | 92 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 39 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
813 | 126 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
77 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
267 | 62 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
136 | 48 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
161 | 31 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
214 | 42 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
214 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
813 | 126 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
184 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2594 | 573 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1924 | 420 |
| Amlodipine Besylate | Amlodipine Besylate | 1496 | 347 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1477 | 321 |
| Gabapentin | Gabapentin | 1410 | 386 |
| Furosemide | Furosemide | 1351 | 329 |
| Potassium Chloride | Potassium Chloride | 1332 | 290 |
| Lisinopril | Lisinopril | 1253 | 331 |
| Metformin Hcl | Metformin Hcl | 1039 | 265 |
| Clopidogrel | Clopidogrel Bisulfate | 922 | 179 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 839 | 297 |
| Eliquis | Apixaban | 813 | 126 |
| Alprazolam | Alprazolam | 805 | 211 |
| Trazodone Hcl | Trazodone Hcl | 796 | 206 |
| Metoprolol Tartrate | Metoprolol Tartrate | 790 | 185 |
| Omeprazole | Omeprazole | 765 | 162 |
| Tamsulosin Hcl | Tamsulosin Hcl | 758 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 707 | 165 |
| Carvedilol | Carvedilol | 667 | 162 |
| Losartan Potassium | Losartan Potassium | 635 | 155 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 600 | 154 |
| Metoprolol Succinate | Metoprolol Succinate | 593 | 146 |
| Topiramate | Topiramate | 576 | 137 |
| Baclofen | Baclofen | 574 | 154 |
| Mirtazapine | Mirtazapine | 520 | 153 |
| Montelukast Sodium | Montelukast Sodium | 518 | 119 |
| Donepezil Hcl | Donepezil Hcl | 510 | 108 |
| Meloxicam | Meloxicam | 507 | 139 |
| Famotidine | Famotidine | 486 | 130 |
| Hydrochlorothiazide | Hydrochlorothiazide | 472 | 112 |
| Duloxetine Hcl | Duloxetine Hcl | 470 | 97 |
| Quetiapine Fumarate | Quetiapine Fumarate | 463 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 442 | 154 |
| Sertraline Hcl | Sertraline Hcl | 442 | 102 |
| Januvia | Sitagliptin Phosphate | 439 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 436 | 101 |
| Buspirone Hcl | Buspirone Hcl | 435 | 107 |
| Hydralazine Hcl | Hydralazine Hcl | 434 | 107 |
| Levetiracetam | Levetiracetam | 408 | 96 |
| Tramadol Hcl | Tramadol Hcl | 398 | 125 |
| Divalproex Sodium | Divalproex Sodium | 393 | 109 |
| Benztropine Mesylate | Benztropine Mesylate | 391 | 109 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 381 | 122 |
| Ropinirole Hcl | Ropinirole Hcl | 381 | 85 |
| Sucralfate | Sucralfate | 373 | 78 |
| Ventolin Hfa | Albuterol Sulfate | 337 | 117 |
| Olanzapine | Olanzapine | 334 | 79 |
| Ibuprofen | Ibuprofen | 332 | 98 |
| Diclofenac Sodium | Diclofenac Sodium | 327 | 91 |
| Simvastatin | Simvastatin | 318 | 82 |
| Aripiprazole | Aripiprazole | 309 | 67 |
| Alcohol Pads | Alcohol Antiseptic Pads | 302 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 301 | 60 |
| Farxiga | Dapagliflozin Propanediol | 294 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 291 | 62 |
| Lamotrigine | Lamotrigine | 285 | 66 |
| Prednisone | Prednisone | 275 | 169 |
| Allopurinol | Allopurinol | 271 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 267 | 62 |
| Spironolactone | Spironolactone | 259 | 67 |
| Symbicort | Budesonide/Formoterol Fumarate | 259 | 92 |
| Ondansetron Hcl | Ondansetron Hcl | 253 | 112 |
| Dicyclomine Hcl | Dicyclomine Hcl | 249 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 245 | 96 |
| Fluoxetine Hcl | Fluoxetine Hcl | 245 | 60 |
| Celecoxib | Celecoxib | 237 | 54 |
| Risperidone | Risperidone | 233 | 52 |
| Prazosin Hcl | Prazosin Hcl | 228 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 224 | 48 |
| Primidone | Primidone | 223 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 221 | 65 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 219 | 50 |
| Propranolol Hcl | Propranolol Hcl | 215 | 63 |
| Rexulti | Brexpiprazole | 214 | 42 |
| Linzess | Linaclotide | 196 | 51 |
| Midodrine Hcl | Midodrine Hcl | 196 | 51 |
| Memantine Hcl | Memantine Hcl | 192 | 45 |
| Lactulose | Lactulose | 188 | 75 |
| Gemtesa | Vibegron | 184 | 47 |
| Ozempic | Semaglutide | 183 | 59 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 183 | 43 |
| Clonidine Hcl | Clonidine Hcl | 181 | 60 |
| Amitriptyline Hcl | Amitriptyline Hcl | 178 | 54 |
| Trulicity | Dulaglutide | 178 | 44 |
| Oxybutynin Chloride | Oxybutynin Chloride | 171 | 39 |
| Jardiance | Empagliflozin | 167 | 39 |
| Atenolol | Atenolol | 166 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 165 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 52 |
| Xarelto | Rivaroxaban | 161 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 152 | 133 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 151 | 49 |
| Vascepa | Icosapent Ethyl | 150 | 30 |
| Oxcarbazepine | Oxcarbazepine | 148 | 27 |
| Meclizine Hcl | Meclizine Hcl | 147 | 44 |
| Nifedipine Er | Nifedipine | 145 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 56 |
| Azithromycin | Azithromycin | 143 | 123 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 142 | 43 |
| Ezetimibe | Ezetimibe | 142 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 141 | 39 |
| Invega Sustenna | Paliperidone Palmitate | 136 | 48 |
| Clonazepam | Clonazepam | 135 | 37 |
| Metformin Hcl Er | Metformin Hcl | 130 | 29 |
| Pregabalin | Pregabalin | 130 | 48 |
| Amoxicillin | Amoxicillin | 129 | 97 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 123 | 96 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 120 | 27 |
| Lovastatin | Lovastatin | 120 | 26 |
| Carbamazepine | Carbamazepine | 118 | 33 |
| Nystatin | Nystatin | 118 | 65 |
| Torsemide | Torsemide | 118 | 25 |
| Lorazepam | Lorazepam | 117 | 28 |
| Clozapine | Clozapine | 116 | 20 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 115 | 33 |
| Bumetanide | Bumetanide | 114 | 31 |
| Tradjenta | Linagliptin | 114 | 18 |
| Entresto | Sacubitril/Valsartan | 113 | 25 |
| Levofloxacin | Levofloxacin | 113 | 89 |
| Fenofibrate | Fenofibrate Nanocrystallized | 111 | 23 |
| Colchicine | Colchicine | 110 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 110 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 109 | 33 |
| Glimepiride | Glimepiride | 108 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 105 | 27 |
| Cilostazol | Cilostazol | 104 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 81 |
| Naproxen | Naproxen | 102 | 33 |
| Metoclopramide Hcl | Metoclopramide Hcl | 100 | 24 |
| Ondansetron Odt | Ondansetron | 100 | 54 |
| Mounjaro | Tirzepatide | 99 | 25 |
| Lithium Carbonate | Lithium Carbonate | 97 | 20 |
| Haloperidol | Haloperidol | 96 | 32 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 95 | 45 |
| Tresiba Flextouch U-100 | Insulin Degludec | 95 | 24 |
| Glipizide | Glipizide | 92 | 22 |
| Myrbetriq | Mirabegron | 91 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 87 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 37 |
| Bupropion Xl | Bupropion Hcl | 85 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 84 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 83 | 42 |
| Insulin Lispro | Insulin Lispro | 83 | 35 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 83 | 27 |
| Estradiol | Estradiol | 78 | 19 |
| Fluconazole | Fluconazole | 78 | 44 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 77 | 59 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 19 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 76 | 20 |
| Finasteride | Finasteride | 75 | 24 |
| Latanoprost | Latanoprost | 75 | 28 |
| Bydureon Bcise | Exenatide Microspheres | 73 | suppressed |
| Nitroglycerin | Nitroglycerin | 73 | 35 |
| Haloperidol Decanoate | Haloperidol Decanoate | 72 | 24 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 71 | 18 |
| Roflumilast | Roflumilast | 71 | 21 |
| Paliperidone Er | Paliperidone | 70 | 16 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 70 | 18 |
| Atomoxetine Hcl | Atomoxetine Hcl | 69 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 16 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 68 | 30 |
| Solifenacin Succinate | Solifenacin Succinate | 66 | 19 |
| Metronidazole | Metronidazole | 65 | 53 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 18 |
| Methocarbamol | Methocarbamol | 64 | 28 |
| Lurasidone Hcl | Lurasidone Hcl | 63 | 19 |
| Scopolamine | Scopolamine | 63 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 62 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | 35 |
| Xifaxan | Rifaximin | 59 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 58 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 57 | 28 |
| Carbamazepine Er | Carbamazepine | 56 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 11 |
| Acyclovir | Acyclovir | 53 | 16 |
| Cephalexin | Cephalexin | 53 | 45 |
| Diazepam | Diazepam | 53 | 21 |
| Doxepin Hcl | Doxepin Hcl | 53 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 41 |
| Rybelsus | Semaglutide | 52 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 52 | suppressed |
| Nyamyc | Nystatin | 51 | 30 |
| Diltiazem Hcl | Diltiazem Hcl | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 25 |
| Vraylar | Cariprazine Hcl | 50 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 49 | 42 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 49 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 48 | 48 |
| Humalog | Insulin Lispro | 48 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 48 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 13 |
| Verapamil Hcl | Verapamil Hcl | 48 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 20 |
| Lacosamide | Lacosamide | 47 | 15 |
| Megestrol Acetate | Megestrol Acetate | 47 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | 11 |
| Levemir Flexpen | Insulin Detemir | 45 | 22 |
| Brilinta | Ticagrelor | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 40 |
| Levemir | Insulin Detemir | 44 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Novolog | Insulin Aspart | 44 | 16 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 44 | 44 |
| Digoxin | Digoxin | 42 | suppressed |
| Movantik | Naloxegol Oxalate | 41 | suppressed |
| Repatha Sureclick | Evolocumab | 41 | 13 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 41 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 25 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 38 | 15 |
| Amantadine | Amantadine Hcl | 38 | 12 |
| Creon | Lipase/Protease/Amylase | 37 | 11 |
| Insulin Aspart | Insulin Aspart | 37 | 21 |
| Phenobarbital | Phenobarbital | 37 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | suppressed |
| Austedo | Deutetrabenazine | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | 22 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 35 | 14 |
| Breyna | Budesonide/Formoterol Fumarate | 34 | 17 |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 21 |
| Techlite Pen Needle | Pen Needle, Diabetic | 34 | 18 |
| Naltrexone Hcl | Naltrexone Hcl | 33 | 16 |
| Desmopressin Acetate | Desmopressin Acetate | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | 14 |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Enulose | Lactulose | 31 | 16 |
| Ketoconazole | Ketoconazole | 31 | 14 |
| Risperdal Consta | Risperidone Microspheres | 30 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 30 | 17 |
| Lithium Carbonate Er | Lithium Carbonate | 29 | suppressed |
| Nystop | Nystatin | 29 | 15 |
| Temazepam | Temazepam | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | 14 |
| Lumigan | Bimatoprost | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 19 |
| Uzedy | Risperidone | 28 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Glucagon Emergency Kit | Glucagon | 27 | 15 |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 25 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Fentanyl | Fentanyl | 23 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 23 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 23 | 15 |
| Cefdinir | Cefdinir | 22 | 18 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 17 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 12 |
| Dutasteride | Dutasteride | 18 | suppressed |
| Permethrin | Permethrin | 18 | 12 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 16 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 16 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | 12 |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Aristada | Aripiprazole Lauroxil | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 12 |
| Letrozole | Letrozole | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Desoximetasone | Desoximetasone | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,795.96 · 52 records | Janssen Pharmaceuticals, Inc | ABRYSVO, ARISTADA, BREZTRI, COBENFY, COMIRNATY, Dexcom G6 Transmitter, FANAPT, FARXIGA, GEMTESA, JARDIANCE, LYBALVI, OTEZLA, PREVNAR 20, REPATHA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, VOQUEZNA, ZENPEP | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error